Identification of Small Molecules that Disrupt Signaling between ABL and Its Positive Regulator RIN1
Open Access
- 26 March 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0121833
Abstract
Constitutively active BCR-ABL kinase fusions are causative mutations in the pathogenesis of hematopoietic neoplasias including chronic myelogenous leukemia (CML). Although these fusions have been successfully targeted with kinase inhibitors, drug-resistance and relapse continue to limit long-term survival, highlighting the need for continued innovative drug discovery. We developed a time-resolved Förster resonance energy transfer (TR-FRET) -based assay to identify compounds that disrupt stimulation of the ABL kinase by blocking its ability to bind the positive regulator RIN1. This assay was used in a high throughput screen (HTS) of two small molecule libraries totaling 444,743 compounds. 708 confirmed hits were counter-screened to eliminate off-target inhibitors and reanalyzed to prioritize compounds with IC50 values below 10 μM. The CML cell line K562 was then used to identify five compounds that decrease MAPK1/3 phosphorylation, which we determined to be an indicator of RIN1-dependent ABL signaling. One of these compounds is a thiadiazole, and the other four are structurally related acyl piperidine amides. Notably, these five compounds lower cellular BCR-ABL1 kinase activity by blocking a positive regulatory interaction rather than directly inhibiting ABL catalytic function.Keywords
This publication has 42 references indexed in Scilit:
- Ponatinib in Refractory Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2012
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood, 2012
- ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1Leukemia, 2010
- Activation of Aortic Endothelial Cells by Oxidized Phospholipids: A Phosphoproteomic AnalysisJournal of Proteome Research, 2010
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsNature, 2010
- Enhancement of ABL Kinase Catalytic Efficiency by a Direct Binding Regulator Is Independent of Other Regulatory MechanismsJournal of Biological Chemistry, 2008
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- The antioxidant properties of theaflavins and their gallate esters — radical scavengers or metal chelators?FEBS Letters, 1996
- Tannin interactions with a full‐length human salivary proline‐rich protein display a stronger affinity than with single proline‐rich repeatsFEBS Letters, 1996
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 1988